0001014108-25-000065.txt : 20251022
0001014108-25-000065.hdr.sgml : 20251022
20251022170648
ACCESSION NUMBER: 0001014108-25-000065
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering
FILED AS OF DATE: 20251022
DATE AS OF CHANGE: 20251022
EFFECTIVENESS DATE: 20251022
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bond Biosciences, Inc.
CENTRAL INDEX KEY: 0001824224
ORGANIZATION NAME:
EIN: 810933527
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-523360
FILM NUMBER: 251410793
BUSINESS ADDRESS:
STREET 1: 555 MADISON AVENUE
STREET 2: SUITE 1201
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 650-804-2139
MAIL ADDRESS:
STREET 1: 555 MADISON AVENUE
STREET 2: SUITE 1201
CITY: NEW YORK
STATE: NY
ZIP: 10022
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001824224
Bond Biosciences, Inc.
170 English Landing Drive
Suite 201B
Parkville
MO
MISSOURI
64152
650-804-2139
DELAWARE
Fetterex Biopharma, Inc.
None
Corporation
true
Michael
A.
Riley
170 English Landing Drive
Suite 201B
Parkville
MO
MISSOURI
64152
Executive Officer
Director
Cory
Berkland
170 English Landing Drive
Suite 201B
Parkville
MO
MISSOURI
64152
Executive Officer
Director
Timothy
Opler
170 English Landing Drive
Suite 201B
Parkville
MO
MISSOURI
64152
Director
Michael
Beckloff
170 English Landing Drive
Suite 201B
Parkville
MO
MISSOURI
64152
Director
Other Health Care
Decline to Disclose
- 06b
true
0001014108-24-000043
2024-08-22
false
true
Simple Agreement for Future Equity
false
0
Collage Venture Partners, LLC
316063
Stonehaven, LLC
118913
929 Alton Road
Suite 500
Miami Beach
FL
FLORIDA
33139
AL
ALABAMA
CA
CALIFORNIA
CO
COLORADO
FL
FLORIDA
GA
GEORGIA
IL
ILLINOIS
IN
INDIANA
KS
KANSAS
ME
MAINE
MD
MARYLAND
MI
MICHIGAN
MO
MISSOURI
NJ
NEW JERSEY
NY
NEW YORK
NC
NORTH CAROLINA
PA
PENNSYLVANIA
TN
TENNESSEE
TX
TEXAS
UT
UTAH
WI
WISCONSIN
false
4500000
3815000
685000
false
83
267050
0
0
false
Bond Biosciences, Inc.
/s/Michael A. Riley
Michael A. Riley
Chief Executive Officer
2025-10-22